Horizons

Opinion & insight from our Clinical Steering Group

Horizons, led by a team of experts from our Clinical Steering Group, is a series of scientific articles which take a deep dive into the emerging trends in the healthcare landscape, kickstarting a dialogue about how treatments and strategies should be best implemented for the benefit of patients.

We're discussing new treatments, especially in oncology, and how they are set to disrupt healthcare practices in the coming years. Some of the topics we'll be tackling include:

  • Antibody-drug conjugates

  • Immuno-oncology

  • Oral proteasome inhibitors – multiple myeloma

  • CDK 4&6

  • Biosimilars – both as a class and specifics

  • PARP inhibitors

  • CAR-T

 

Blog Posts

Marshall Pearce

Antibody-drug conjugates (ADCs)

Posted 20 days ago

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Related learning zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

Visit Chronic Lymphocytic Leukaemia (CLL)

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

Visit Prostate Cancer